The SURPASS-CVOT trial examining tirzepatide's cardiovascular outcomes is ongoing, and results are expected to inform future labeling
Last August, the Danish company issued a press release claiming a 2.4 mg dose of semaglutide (Wegovy) could reduce the risk of major adverse cardiovascular events by 20 per cent in overweight or obese adults, boosting its stock price by 17 per cent
The trade-off is local side effects that injections do not cause: mouth irritation, taste disturbances, tongue numbness, and throat irritation
If symptoms after eating are severe, persistent, or prevent normal food or fluid intake, seek medical advice to rule out dehydration or other complications
Slower motility also reduces the clearance of those gases, so the same amount of gas feels louder and more uncomfortable